The influence of prostate‐specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7–10 prostate cancer in a repeat biopsy setting

BJU International - Tập 119 Số 5 - Trang 724-730 - 2017
Nienke L. Hansen1,2, Tristan Barrett1,3, Brendan Koo1,3, Andrew Doble1,4, Vincent J. Gnanapragasam5,1, Anne Y. Warren1,6, Christof Kastner1,4, Ola Bratt1,4
1CamPARI Clinic, Addenbrooke’s Hospital & University of Cambridge, Cambridge, UK
2Department of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany
3Department of Radiology, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
4Department of Urology, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
5Academic Urology Group, Department of Surgery and Oncology, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK
6Department of Pathology, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK

Tóm tắt

ObjectivesTo evaluate the influence of prostate‐specific antigen density (PSAD) on positive (PPV) and negative (NPV) predictive values of multiparametric magnetic resonance imaging (mpMRI) to detect Gleason score ≥7 cancer in a repeat biopsy setting.Patients and MethodsRetrospective study of 514 men with previous prostate biopsy showing no or Gleason score 6 cancer. All had mpMRI, graded 1–5 on a Likert scale for cancer suspicion, and subsequent targeted and 24‐core systematic image‐fusion guided transperineal biopsy in 2013–2015. The NPVs and PPVs of mpMRIs for detecting Gleason score ≥7 cancer were calculated (±95% confidence intervals) for PSAD ≤0.1, 0.1–0.2, ≤0.2 and >0.2 ng/mL/mL, and compared by chi‐square test for linear trend.ResultsGleason score ≥7 cancer was detected in 31% of the men. The NPV of Likert 1–2 mpMRI was 0.91 (±0.04) with a PSAD of ≤0.2 ng/mL/mL and 0.71 (±0.16) with a PSAD of >0.2 ng/mL/mL (P = 0.003). For Likert 3 mpMRI, PPV was 0.09 (±0.06) with a PSAD of ≤0.2 ng/mL/mL and 0.44 (±0.19) with a PSAD of >0.2 ng/mL/mL (P = 0.002). PSAD also significantly affected the PPV of Likert 4–5 mpMRI lesions: the PPV was 0.47 (±0.08) with a PSAD of ≤0.2 ng/mL/mL and 0.66 (±0.10) with a PSAD of >0.2 ng/mL/mL (P < 0.001).ConclusionIn a repeat biopsy setting, a PSAD of ≤0.2 ng/mL/mL is associated with low detection of Gleason score ≥7 prostate cancer, not only in men with negative mpMRI, but also in men with equivocal imaging. Surveillance, rather than repeat biopsy, may be appropriate for these men. Conversely, biopsies are indicated in men with a high PSAD, even if an mpMRI shows no suspicious lesion, and in men with an mpMRI suspicious for cancer, even if the PSAD is low.

Từ khóa


Tài liệu tham khảo

10.1038/nrurol.2013.112

10.1097/PAS.0b013e3182556dcd

10.1016/j.eururo.2014.11.037

10.1038/pcan.2009.42

10.1111/bju.13108

10.1016/j.juro.2011.07.013

10.1111/j.1464-410X.2011.10112.x

10.1111/j.1464-410X.2012.11646.x

10.1016/j.eururo.2016.02.064

10.1016/j.eururo.2013.09.046

National Collaborating Centre for Cancer (UK).Prostate Cancer: Diagnosis and Treatment.Cardiff UK:National Collaborating Centre for Cancer (UK) 2014. Available at:https://www.nice.org.uk/guidance/cg175/evidence/full-guideline-191710765. Accessed August 2016

10.6004/jnccn.2015.0181

10.2214/AJR.14.13285

10.1016/j.eururo.2014.08.079

10.1016/S0022-5347(17)37393-7

10.1016/j.juro.2009.08.139

10.1016/j.juro.2013.05.015

10.1016/j.juro.2013.09.034

10.1002/cncr.29874

10.1016/j.urolonc.2015.01.004

10.1111/bju.13465

10.1016/j.eururo.2013.03.030

10.1097/01.pas.0000173646.99337.b1

10.1007/s00330-011-2377-y

10.1016/j.eururo.2015.08.052

10.1111/bju.12132

10.1056/NEJMoa031918

10.1111/bju.13458

10.1016/j.eururo.2007.08.006

10.1016/j.eururo.2015.12.052

10.5489/cuaj.2895

10.1111/bju.12892

Thông tin
Thông tin xuất bản

BJU International

Tập 119 Số 5

724-730

Thông tin tác giả